Singapore, July 16 -- 365mc,South Korea'sleading medical institution specialising in fat reduction treatments, and Israel-based Raziel Therapeutics, a global clinical-stage biopharmaceutical company, have announced a strategic collaboration to jointly advance the clinical and commercial development of RZL-012 inSouth Korea. RZL-012 is an innovative injectable treatment for focal fat reduction that is currently progressing toward Phase 3 trials.

Leveraging its domestic leadership,365mc is rapidly expanding its global presence, with successful market entries inIndonesia,Thailand, andVietnam, and a recent expansion confirmed in the United States, firmly positioning 365mc as a leading international authority in body contouring.

Raziel Thera...